Horm Metab Res 1992; 24(11): 537-540
DOI: 10.1055/s-2007-1003383
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Insulin-Like Growth Factor Binding Protein 1 (IGFBP-1) Levels in Turner Syndrome

S. Cianfarani1 , J. M. P. Holly2 , A. M. Pasquino3 , F. Vaccaro1 , G. L. Spadoni1 , S. Bernardini1 , M. Segni3 , B. Boscherini1
  • 1Department of Pediatrics, 2nd University of Rome, Rome Italy
  • 2Department of Chemical Endocrinology, St. Bartholomew's Hospital, London, United Kingdom
  • 3Department of Pediatrics, 1st University of Rome, Rome, Italy
Further Information

Publication History

1992

1992

Publication Date:
14 March 2008 (online)

Summary

We tested whether IGFBP-1, a modulator of IGF-I action, would play a role in the pathogenesis of growth failure and metabolic picture of Turner syndrome. Fasting serum levels of IGFBP-1 were assessed in nineteen girls with Turner syndrome (aging 6.5 to 17.2 years) by radioimmunoassay. Our patients showed normal values of IGFBP-1 (mean±SD: 68.6±32.5 μg/l, range: 16 to 134 μg/l; range for age and pubertal stage-matched normal children: 15 to 180 μg/l). IGFBP-1 levels inversely correlated with bone age (p < 0.05), weight (p < 0.001), percentage of ideal body weight (p < 0.002) and body mass index (BMI) (p < 0.001). Our results seem to rule out a role of IGFBP-1 in the pathogenesis of growth failure in Turner syndrome. The close inverse relationship between IGFBP-1 levels and BMI suggests the serum concentrations of IGFBP-1 to be regulated by the nutritional status. Due to IGFBP-1 inhibiting action on IGF biological activity, the reduction of IGFBP-1 levels in overweight subjects might represent a mechanism to enhance the IGF insulin-like activity, thus supplementing the insulin action.